

DAFTAR PUSTAKA

- World Health Organization. Global Tuberculosis Report 2021; World Health Organization: Geneva, Switzerland, 2021.
- World Health Organization. Implementing the End TB Strategy. *Antimicrob. Agents Chemother.* 2014, 58, 7250–7257.
- World Health Organization. WHO Treatment of Tuberculosis Guidelines, 4th ed.; World Health Organization: Geneva, Switzerland, 2010.
- Falzon, D.; Schünemann, H.J.; Harausz, E.; González-Angulo, L.; Lienhardt, C.; Jaramillo, E.; Weyer, K. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. *Eur. Respir. J.* 2017, 49, 1602308.
- van Deun, A.; Maug, A.K.J.; Salim, M.A.H.; Das, P.K.; Sarker, M.R.; Daru, P.; Rieder, H.L. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. *Am. J. Respir. Crit. Care Med.* 2010, 182, 684–692.
- Piubello, A.; Harouna, S.H.; Souleymane, M.B.; Boukary, I.; Morou, S.; Daouda, M.; Hanki, Y.; van Deun, A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: No relapses. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis.* 2014, 18, 1188–1194.
- Kuaban, C.; Noeske, J.; Rieder, H.L.; Aït-Khaled, N.; Abena Foe, J.L.; Trébucq, A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. *Int. J. Tuberc. Lung Dis. Off. J. Int. Union Against Tuberc. Lung Dis.* 2015, 19, 517–524.
- Diacon, A.H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee, R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Churchyard, G.; et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. *N. Engl. J. Med.* 2009, 360, 2397–2405.
- Diacon, A.H.; Pym, A.; Grobusch, M.P.; de los Rios, J.M.; Gotuzzo, E.; Vasilyeva, I.; Lemaine, V.; Andries, K.; Bakare, N.; De Marez, T.; et al. Multidrug-resistant

- tuberculosis and culture conversion with bedaquiline. *N. Engl. J. Med.* 2014, 371, 723–732.
- Gler, M.T.; Skripconoka, V.; Sanchez-Garavito, E.; Xiao, H.; Cabrera-Rivero, J.L.; Vargas-Vasquez, D.E.; Gao, M.; Awad, M.; Park, S.-K.; Sun Shim, T.; et al. Delamanid for multidrug-resistant pulmonary tuberculosis. *N. Engl. J. Med.* 2012, 366, 2151–2160.
- Espinosa-Pereiro J, Sánchez-Montalvá A, Aznar ML, Espiau M. MDR Tuberculosis Treatment. *Med.* 2022;58(2):1-34. doi:10.3390/medicina58020188
- Denis, Doreen, Claire, et.all (2019). *Multidrug-resistant tuberculosis outbreak associated with poor treatment adherence and delayed treatment: Arua District, Uganda, 2013–2017*. *BMC Infectious Diseases* (2019) 19:387 <https://doi.org/10.1186/s12879-019-4014-3>.
- Khawbung, J. L., Nath, D. & Chakraborty, S. Drug resistant Tuberculosis: A review. *Comp. Immunol. Microbiol. Infect. Dis.* **74**, 101574 (2021).
- Saleh, S. & Syahridha, S. FACTOR RELEATED OF ANTI-TUBERCULOSIS DRUG RESISTENCY ON PULMONARY TUBERCULOSIS PASIENT IN LABUANG BAJI HOSPITAL MAKASSAR. *Indones. J. Trop. Infect. Dis.* **7**, 40–44 (2018).
- Alghamdi, S. *et al.* Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis. *Molecules* **25**, 5685 (2020).
- Surya, A. *et al.* Quality Tuberculosis Care in Indonesia: Using Patient Pathway Analysis to Optimize Public–Private Collaboration. *J. Infect. Dis.* **216**, S724–S732 (2017).
- Dashboard TB - TBC Indonesia. <https://tbindonesia.or.id/pustaka-tbc/dashboard-tb/>.
- Jameson, J. L. *Harrison's principles of internal medicine*. (McGraw-Hill Education, 2018).Indonesia, P. D. P. Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia. *Jakarta PDPI* 20–30 (2011).
- Widyasrini, E. R., Probandari, A. N. & Reviono, R. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. *J. Epidemiol. Public Heal.* **2**, 45–57 (2017).

- Sarwani SR, D. & Nurlaela, S. Faktor risiko multidrug resistant tuberculosis (MDR-TB). *KEMAS J. Kesehatan. Masy.* **8**, 60–66 (2012).
- Adenji, Knoll, Loots (2020). *Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus*. 2020 Jul;104(13):5633-5662. doi: 10.1007/s00253-020-10606-y. Epub 2020 May 5.
- Alghamdi, S, et al. (2020). *Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis*. *Molecules* 2020, 25, 5685; doi:10.3390/molecules25235685
- Sarwani, Nurlela, dkk (2012). *Factor risiko multidrug resistant tuberculosis (MDR-TB)*. Vincent. (2019). *pola resistensi antibiotik pada kasus tb kambuh yang resisten di puskesmas kramat jati, jakarta timur pada tahun 2016-2018*.
- Chan-yeung, leung, et. all (2013) *Prevalence and predictors of default from tuberculosis treatment in Hongkong*. *Hongkong Med J.* 2003;9:263-8.
- Mahmoudi A, Iseman MD (2016). *Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance*. *JAMA.* 1993;270:65-8.
- Nugrahaeni, Malik. (2013). *ANALISIS PENYEBAB RESISTENSI OBAT ANTI TUBERKULOSIS* Dyan Kunthi Nugrahaeni, Upep Saiful Malik. DOI <http://dx.doi.org/10.15294/kemas.v11i1.3341>
- Tun-Chieh, Po-Liang Lu, Chun-Yu, et al. (2017). *Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis*. *International Society for Infectious Diseases*. Published by Elsevier Ltd. All rights reserved. doi:10.1017/j.ijid.2017.11.0008
- Fan Wu, Jing Zhang, Fuhang Song, et. all (2016). *Chrysoerythrin A Derivatives for the Treatment of Multi-Drug Resistant Tuberculosis*. [ACS Central Science](#)
- Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. *Int J Infect Dis.* 2020;92:S15-S25. doi:10.1016/j.ijid.2020.01.042
- Mantefardo B, Sisay G. Case report: Kanamycin ototoxicity and mdr-tb treatment regimen. *Int Med Case Rep J.* 2021;14:815-817. doi:10.2147/IMCRJ.S336259

- Lange C, Chesov D, Heyckendorf J, Leung CC, Udwadia Z, Dheda K. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. *Respirology*. 2018;23(7):656-673. doi:10.1111/resp.13304
- Cornish R. A case study of a patient with multidrug-resistant tuberculosis. *Br J Nurs*. 2018;27(14):806-809. doi:10.12968/bjon.2018.27.14.806
- Perrin C, Athersuch K, Elder G, Martin M, Alsalhani A. Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study. *BMJ Glob Heal*. 2022;7(4):1-9. doi:10.1136/bmjgh-2021-007490
- Khan U, Huerga H, Khan AJ, et al. The endTB observational study protocol: Treatment of MDR-TB with bedaquiline or delamanid containing regimens. *BMC Infect Dis*. 2019;19(1):1-9. doi:10.1186/s12879-019-4378-4
- Wirth D, Dass R, Hettle R. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. *BMC Health Serv Res*. 2017;17(1):1-11. doi:10.1186/s12913-017-2118-2
- Hafner R, Groote-bidlingmaier F Von, Lama JR. PATIENTS WITH RIFAMPICIN-RESISTANT-TB: A RANDOMIZED. 2022;21(7):975-983. doi:10.1016/S1473-3099(20)30770-2.QT